Compare ONEW & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | NERV |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 189.1M |
| IPO Year | 2020 | 2014 |
| Metric | ONEW | NERV |
|---|---|---|
| Price | $12.91 | $4.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $16.75 | $4.00 |
| AVG Volume (30 Days) | ★ 183.0K | 75.4K |
| Earning Date | 01-29-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $2.23 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.63 | N/A |
| 52 Week Low | $10.14 | $1.15 |
| 52 Week High | $21.00 | $12.46 |
| Indicator | ONEW | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 52.76 |
| Support Level | $13.18 | $3.75 |
| Resistance Level | $15.25 | $4.49 |
| Average True Range (ATR) | 0.81 | 0.36 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 9.46 | 53.00 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.